Contact

Our portfolio

Regenesance

Regenesance focuses on antibody engineering to treat neurodegenerative diseases and immune-mediated disorders. The company licenses its technology to Complement Pharma, aiming to develop therapies for conditions like ALS and multiple sclerosis. The company leverages groundbreaking research to improve patient outcomes.

  • Institute: Amsterdam UMC
Industry: Immunology, Therapeutics
  • Founding year: 2009
Visit website

Want to get in contact about Regenesance?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Hipper Therapeutics
Boosting recovery and confidence in elderly hip fracture patients with data-driven rehabilitation technology.
PacingCure
Developing gene therapy solutions for heart rhythm disorders.
AviSia Therapeutics
Modulating immune responses with glycan-modified antigens for the treatment of Type 1 Diabetes.
Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
Hipper Therapeutics
Boosting recovery and confidence in elderly hip fracture patients with data-driven rehabilitation technology.
PacingCure
Developing gene therapy solutions for heart rhythm disorders.
AviSia Therapeutics
Modulating immune responses with glycan-modified antigens for the treatment of Type 1 Diabetes.
Figlinq
Enabling secure AI-assisted data management, analysis, visualization, sharing, and FAIR publishing.
Explore full AAV portfolio
Contact